Our original publication showns some errors in the structures in Schemes 9, 15, 20, and 22. The corrected schemes are shown in this Correction.

The wrong configuration was depicted for C-4 (carrying the OH group) in the pyranose ring of doxorubicin in Scheme 9; the corrected scheme ([Scheme 1](#C1){ref-type="fig"}) is shown below:

![Corrected Scheme 9 of the original article. N/P-doped hollow CDs for efficient drug delivery of doxorubicin.](Beilstein_J_Org_Chem-13-1136-g001){#C1}

The NH group was missing at C-2 of the GlcNAc residues in Scheme 15; the corrected scheme ([Scheme 2](#C2){ref-type="fig"}) is shown below:

![Corrected Scheme 15 of the original article. N/P-doped green-emissive CDs working in tandem with hyaluronic acid-coated AuNPs to monitor hyaluronidase activity.](Beilstein_J_Org_Chem-13-1136-g002){#C2}

The carbohydrate polymers in Schemes 20 and 22 were depicted as poly-peroxide with one oxygen atom too many in the repeating unit, repectively; the corrected schemes ([Scheme 3](#C3){ref-type="fig"} and [Scheme 4](#C4){ref-type="fig"}) are shown below:

![Corrected Scheme 20 of the original article. Different polysaccharide-derived CDs in the presence of PEG-200 and how the starting material composition is conferred to the CD products.](Beilstein_J_Org_Chem-13-1136-g003){#C3}

![Corrected Scheme 22 of the original article. Hyaluronic acid (HA) and glycine-derived CDs, suspected to be decorated in unreacted HA, allowing receptor-mediated cell uptake.](Beilstein_J_Org_Chem-13-1136-g004){#C4}
